EP3174987A4 - Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables - Google Patents

Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables Download PDF

Info

Publication number
EP3174987A4
EP3174987A4 EP15827888.7A EP15827888A EP3174987A4 EP 3174987 A4 EP3174987 A4 EP 3174987A4 EP 15827888 A EP15827888 A EP 15827888A EP 3174987 A4 EP3174987 A4 EP 3174987A4
Authority
EP
European Patent Office
Prior art keywords
reactions
mrgprb2
mrgprx2
prevent
cell based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15827888.7A
Other languages
German (de)
English (en)
Other versions
EP3174987A1 (fr
EP3174987B1 (fr
Inventor
Xinzhong Dong
Benjamin MCNEIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP3174987A1 publication Critical patent/EP3174987A1/fr
Publication of EP3174987A4 publication Critical patent/EP3174987A4/fr
Application granted granted Critical
Publication of EP3174987B1 publication Critical patent/EP3174987B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Animal Husbandry (AREA)
EP15827888.7A 2014-08-01 2015-07-31 Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables Active EP3174987B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462032350P 2014-08-01 2014-08-01
PCT/US2015/043116 WO2016019246A1 (fr) 2014-08-01 2015-07-31 Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables

Publications (3)

Publication Number Publication Date
EP3174987A1 EP3174987A1 (fr) 2017-06-07
EP3174987A4 true EP3174987A4 (fr) 2018-02-21
EP3174987B1 EP3174987B1 (fr) 2023-10-11

Family

ID=55218352

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15827888.7A Active EP3174987B1 (fr) 2014-08-01 2015-07-31 Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables

Country Status (8)

Country Link
US (2) US10696971B2 (fr)
EP (1) EP3174987B1 (fr)
JP (2) JP2017524382A (fr)
CN (1) CN107002087B (fr)
AU (1) AU2015296135A1 (fr)
CA (1) CA2957025A1 (fr)
ES (1) ES2961366T3 (fr)
WO (1) WO2016019246A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3528809A4 (fr) 2016-10-18 2020-06-10 Emergo Therapeutics, Inc. Stabilisateurs de mastocytes pour le traitement d'états inflammatoires chroniques
JP2020523992A (ja) 2017-06-16 2020-08-13 ザ ジョンズ ホプキンス ユニバーシティ Ｇタンパク質共役受容体媒介症状を治療するための組成物および方法
CN107142325A (zh) * 2017-06-28 2017-09-08 西安交通大学 一种用于药物类过敏反应敏感人群筛查的基因标志物及其应用
CN108398517A (zh) * 2018-02-11 2018-08-14 湖南正清制药集团股份有限公司 一种筛查正清风痛宁制剂中潜在致敏组分的方法
WO2020229648A1 (fr) 2019-05-16 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de traitement d'une inflammation de type 2 ou d'une maladie dépendant des mastocytes
CN110240643B (zh) * 2019-05-31 2021-05-28 西安交通大学 一种用于制备类过敏反应的双抗夹心试剂盒配对抗体的多肽及其应用
CN110229228B (zh) * 2019-05-31 2021-05-28 西安交通大学 一种对类过敏反应特异性受体mrgprx2蛋白的具有免疫原性的多肽及其应用
CN110229227B (zh) * 2019-05-31 2021-05-28 西安交通大学 一种用于制备elisa鼠单克隆包被抗体和兔多克隆检测抗体的多肽及其应用
CN110204607B (zh) * 2019-05-31 2021-04-20 西安交通大学 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用
CN110204606B (zh) * 2019-05-31 2021-04-20 西安交通大学 一种用于制备兔多克隆抗体的多肽及其应用
KR102494928B1 (ko) * 2020-03-31 2023-02-03 재단법인 아산사회복지재단 Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법
CN111500708A (zh) * 2020-05-08 2020-08-07 中南大学湘雅医院 一种与麻醉药物过敏相关分子标记及其应用和检测试剂盒
WO2022073904A1 (fr) 2020-10-06 2022-04-14 Glaxosmithkline Intellectual Property Development Limited Antagonistes de mrgx2
WO2023230322A1 (fr) * 2022-05-27 2023-11-30 Stealth Biotherapeutics Inc. Adressage de réactions au site d'injection associées à l'administration de l'élamiprétide
CN116814689B (zh) * 2023-06-30 2024-04-05 海湃泰克(北京)生物医药科技有限公司 特异性表达hMRGPRX2的转基因小鼠的构建方法及其应用
CN116855503B (zh) * 2023-08-30 2023-12-08 上海益诺思生物技术股份有限公司 过表达mrgprx2的稳转细胞株及其构建方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016159A1 (fr) * 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, ant
US20050164288A1 (en) * 2000-05-04 2005-07-28 Anderson David J. Pain signaling molecules
EP1876239A1 (fr) * 2005-04-28 2008-01-09 Takeda Pharmaceutical Company Limited Inhibiteur de degranulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2001011022A1 (fr) * 1999-08-05 2001-02-15 Smithkline Beecham Corporation Recepteur edg3 couple a la proteine g des souris
JP2002355052A (ja) 2000-07-07 2002-12-10 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ
EP1340979A3 (fr) 2002-02-27 2004-02-04 Pfizer Limited Récepteur neuropeptidique et son utilisation
JPWO2005028667A1 (ja) 2003-09-19 2006-11-30 独立行政法人理化学研究所 ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法
JP2005304438A (ja) 2004-04-26 2005-11-04 Astellas Pharma Inc 新規スクリーニング方法
WO2007055823A2 (fr) * 2005-10-28 2007-05-18 Multispan, Inc. Lignees cellulaires et anticorps exprimant le gpcr
JP2009060787A (ja) * 2005-11-15 2009-03-26 Gunma Univ Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
EP2238252B1 (fr) * 2008-01-14 2013-07-31 Probiodrug AG Modèles murins portant une mutation du type inactivation du gène de la glutaminyl cyclase
WO2010065085A2 (fr) * 2008-12-01 2010-06-10 The Johns Hopkins University Procédé et composition pour le traitement ou la prévention du prurit
JP2012178985A (ja) * 2011-02-28 2012-09-20 Univ Of Tokyo 骨量増加剤のスクリーニング方法
WO2014202515A1 (fr) * 2013-06-18 2014-12-24 Bayer Pharma Aktiengesellschaft Modulateurs des récepteurs mrg

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016159A1 (fr) * 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, ant
US20050164288A1 (en) * 2000-05-04 2005-07-28 Anderson David J. Pain signaling molecules
EP1876239A1 (fr) * 2005-04-28 2008-01-09 Takeda Pharmaceutical Company Limited Inhibiteur de degranulation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENJAMIN D. MCNEIL ET AL: "Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions", NATURE, vol. 519, no. 7542, 12 March 2015 (2015-03-12), pages 237 - 241, XP055391597, ISSN: 0028-0836, DOI: 10.1038/nature14022 *
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Amino acid sequence of a human G-protein coupled receptor (Ant).", retrieved from EBI accession no. GSP:AAB67654 Database accession no. AAB67654 *
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Human TGR12 protein.", retrieved from EBI accession no. GSP:AEN62979 Database accession no. AEN62979 *
DATABASE Geneseq [online] 20 September 2007 (2007-09-20), "Human Rec168 SEQ ID NO 1.", XP002776681, retrieved from EBI accession no. GSP:AGB13466 Database accession no. AGB13466 *
OKAYAMA YOSHIMICHI ET AL: "Targeting human mast cells expressing g-protein-coupled receptors in allergic diseases", ALLERGOLOGY INTERNATIONAL, JAPANESE SOCIETY OF ALLERGOLOGY, JP, vol. 57, no. 3, 1 September 2008 (2008-09-01), pages 197 - 203, XP002496192, ISSN: 1323-8930, DOI: 10.2332/ALLERGOLINT.R-08-163 *
SAKEEN W. KASHEM ET AL: "G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: Roles of Mas-related genes MrgX1 and MrgX2", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 668, no. 1-2, 1 October 2011 (2011-10-01), NL, pages 299 - 304, XP055434889, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.06.027 *
SUBRAMANIAN HARIHARAN ET AL: "Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 138, no. 3, 20 July 2016 (2016-07-20), pages 700 - 710, XP029712341, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2016.04.051 *
TATEMOTO K ET AL: "Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 349, no. 4, 3 November 2006 (2006-11-03), pages 1322 - 1328, XP024924577, ISSN: 0006-291X, [retrieved on 20061103], DOI: 10.1016/J.BBRC.2006.08.177 *

Also Published As

Publication number Publication date
EP3174987A1 (fr) 2017-06-07
JP2017524382A (ja) 2017-08-31
CN107002087B (zh) 2021-09-28
ES2961366T3 (es) 2024-03-11
JP2020141708A (ja) 2020-09-10
US20200370051A1 (en) 2020-11-26
EP3174987B1 (fr) 2023-10-11
WO2016019246A1 (fr) 2016-02-04
US10696971B2 (en) 2020-06-30
CN107002087A (zh) 2017-08-01
AU2015296135A1 (en) 2017-02-16
CA2957025A1 (fr) 2016-02-04
US20170204419A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
EP3174987A4 (fr) Analyse fondée sur des cellules exprimant mrgprx2/mrgprb2 pour détecter des réactions pseudo-allergiques à un médicament et identifier des antagonistes pour empêcher l'apparition d'effets indésirables
IL246080A0 (en) Saliva bio-sensors and biofuel cells
EP3116801A4 (fr) Réceptacles à double détection
EP3210010A4 (fr) Dispositifs microfluidiques numériques avec capteurs électrochimiques intégrés
EP3040025A4 (fr) Système de détection d'analyte
EP3114716A4 (fr) Cellules de batterie et agencements
EP3149465A4 (fr) Capteur électrochimique pour la détection d'analyte
EP3134719A4 (fr) Capteur de particules avec discrimination d'agents perturbateurs
EP3104151A4 (fr) Capteur de force et structure utilisée en son sein
EP3211392A4 (fr) Capteur de détection d'état
EP3165933A4 (fr) Dispositif de détermination d'état de batterie
EP3193387A4 (fr) Ensemble d'interconnexion de cellule de batterie et de détection de tension, et module de batterie
EP3093907A4 (fr) Élément de batterie comportant un trou
EP3171428A4 (fr) Batterie équipée d'une borne usb
EP3228370A4 (fr) Système de puzzle fonctionnant en concordance avec un dispositif externe
EP3107142A4 (fr) Cellule de batterie à structure renfoncée et asymétrique
EP3116396A4 (fr) Système de détection électrochimique
EP3134724B8 (fr) Cellule électrochimique
EP3109922A4 (fr) Ensemble de détection de tension et d'interconnexion de cellules de batterie, et module de batterie
EP3191578A4 (fr) Cellules exprimant l'apolipoprotéine e et leurs utilisations
EP3167281A4 (fr) Puce de capteur électrochimique
EP3172560A4 (fr) Capteurs électrochimiques, encapsulation et procédés associés
EP3210034A4 (fr) Moniteur de capacité de batterie
EP3212821A4 (fr) Module de bioréacteur électrochimique amélioré et son utilisation
EP3155408A4 (fr) Capteurs et électrodes à solide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

17P Request for examination filed

Effective date: 20170210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7088 20060101ALI20180115BHEP

Ipc: C07K 14/705 20060101ALI20180115BHEP

Ipc: C12N 15/85 20060101ALI20180115BHEP

Ipc: G01N 35/00 20060101ALI20180115BHEP

Ipc: C12N 15/63 20060101AFI20180115BHEP

Ipc: A61P 37/08 20060101ALI20180115BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190328

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015086079

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0015630000

Ipc: A01K0067027000

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12N0015630000

Ipc: A01K0067027000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/08 20060101ALI20230310BHEP

Ipc: C07K 14/705 20060101ALI20230310BHEP

Ipc: G01N 33/50 20060101ALI20230310BHEP

Ipc: C12N 15/113 20100101ALI20230310BHEP

Ipc: C07K 14/72 20060101ALI20230310BHEP

Ipc: A61K 31/7105 20060101ALI20230310BHEP

Ipc: A01K 67/027 20060101AFI20230310BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230503

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015086079

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20231011

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2961366

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240311

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1619266

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231011

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240211

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240112

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240111

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231011

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240212